The goal is to remove the tumor while preserving the bladder and its function. There are different surgical options depending ...

Prophylactic tranexamic acid showed no reduction in blood transfusion rates in open radical cystectomy patients. The trial found no significant differences in secondary outcomes, including estimated ...

Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

You may be eligible for a partial cystectomy (in which only part of your bladder is removed) if the cancer is relatively small, localized to one area, and easily accessible. During a partial ...

A recent study reveals that extended lymphadenectomy offers no survival advantage over standard lymphadenectomy for patients ...

In treatment, the goal is not only to eliminate the cancer but also to preserve organ function whenever possible. Procedures ...

Up to 40% of patients who undergo radical cystectomy are understaged; this would lead to inappropriate therapy if a T2 tumor were misidentified as a T1 tumor. Therefore, re-resection of the bed of ...

(UroToday.com) The 2024 South Central AUA annual meeting included a session on bladder cancer, featuring a presentation by Dr. Chad LaGrange discussing the case for radical cystectomy as treatment for ...

OE, prior cystectomy (group 2) 112 Not reported but all <6 cm 19.60 7.9 ± 4.2 Tubal factor infertility (group 3) 174 6.6 ± 3.5, NS EST: Ethanol scleropathy; FSH: Follicle.stimulating hormone ...

Johnson & Johnson Presented neoadjuvant TAR-200 plus cetrelimab Phase 2 data in patients with muscle-invasive bladder cancer (MIBC) who are ineligible or refuse neoadjuvant platinum-based chemotherapy ...